Clinical trials: Irinotecan-induced Diarrhea
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Malignant Tumor, Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Run-in safety study, to determine the safety of co-administration of irinotecan, raloxifene, and Xiao Chai Hu Tang (XCHT), and to optimize the blood collection time points for pharmacokinetic (PK) study for another randomized…
- Trial name
- NCT04926545
- Testing
- Xiao Chai Hu Tang (XCHT), Raloxifene, FOLFIRI regimen
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Colorectal Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Irinotecan is one of key drug used in the treatment of colorectal cancer. The incidence of irinotecan induced diarrhea varies between 60-90%, with severe diarrhea in 20-40%.
- Trial name
- NCT01410955
- Testing
- Probiotic formula
- Where
- 6 sites in Slovakia
- Volunteers
- 46 people
- Sponsor
- Monsea Ltd.
Xiao Chai Hu Tang, Irinotecan-induced Diarrhea
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide…
- Trial name
- NCT06055179
- Testing
- Xiao Chai Hu Tang (XCHT), Irinotecan regimen, Raloxifene
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Metastatic Colorectal Cancer
Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea
Irinotecan (7-ethyl-10- {4(-1-piperidino)-1-piperidino} carbonyloxy camptothecin) is a semisynthetic camptothecin derivative introduced in the 1980's.
- Trial name
- NCT00255229
- Testing
- Glutamine
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- AHS Cancer Control Alberta
Diarrhea, Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Diarrhea is a relatively common complication in patients with cancer. At its inception, several mechanisms participated; malabsorption on the basis of mucositis induced by chemotherapy, dysbiosis induced by broad-spectrum…
- Trial name
- NCT02819960
- Testing
- Probio-Tec® BG-VCap-6.5
- Where
- Slovakia
- Volunteers
- 233 people
- Sponsor
- S&D Pharma SK s.r.o.
Chemotherapy-induced Diarrhea
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
- Trial name
- LARCID (NCT00582426)
- Testing
- Octreotide Long Acting Release, Standard Treatment
- Where
- 11 sites in Brazil
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Diarrhea
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are…
- Trial name
- NCT00006269
- Testing
- irinotecan hydrochloride, octreotide acetate
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis